Overview

Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Status:
Recruiting

Trial end date:
2024-02-28

Target enrollment:

Participant gender:

Summary

The hypothesis of this study is that the combination of cabiralizumab and nivolumab with neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor infiltrating lymphocytes (TIL) compared to neoadjuvant chemotherapy plus nivolumab in patients with early stage triple-negative breast cancer (TNBC) and improve clinical outcomes.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Collaborator:

Bristol-Myers Squibb

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Nivolumab
Paclitaxel